We recently published a list of 11 best safe shares to buy according to coverage funds. In this article, let’s take a look at where Johnson & Johnson (Nyse: Jnj) is against other better secure shares to buy according to coverage funds.
At the times when you never know what you will wake up the next morning, playing at SAFE seems to be the wisest choice. In the midst of consisted market changes and world uncertainties, it is difficult not to be inclined to reliability. With increasing risks of global recession and political uncertainties, capital protection has become a priority for many. As Charlie Munger said, Vice President of Berkshire Hathaway
“The idea of investing in a company just because it is safe is not necessarily a good idea. But it is a much better idea than to invest in something clearly risky.”
If we think of a “safe” stock, it usually comes to our minds a low -risk stock. Although true, there is even more. A secure stock generally comes from a well -established company that has a strong balance, a decent performance history, solid market positioning and a dividend history. Therefore, when you are looking for a safe stock, it is important to seek not one, not two, but all these metrics. In their entirety, they are usually “blue chip actions” who are leaders in the market for the operation.
Coverage funds, recognized for their strategies and in -depth market understanding, have long defended these stocks due to their reliability and resilience. These managers carefully study market trends, and then weigh companies that are considered to provide both value and predictability.
According to Reuters, the coverage funds flee from the stock of companies that provide what customers want and what they do not need. As the signs of a global recession is becoming more and more evident, the coverage funds are sending their positions to consumer discretion. “The coverage funds pouring consumer’s discretionary shares strongly suggest that they are preparing economic problems, probably a recession,” said Bruno Schnelller, the general director of Erlen Capital Management.
Similarly, a report by Goldman Sachs, which compares the earnings for the vip of coverage funds and the larger market, indicates that the 50 best favorite shares for coverage funds have collected 10% collectively by 2025 in relation to the gain of 3% of the market.
In a “low -risk role that takes place in all the observable markets in the world” by Nardin Baker and Robert Hagen, the differences in performance due to low volatility shares and high volume stocks in developed and emerging capital markets were compared. The results revealed that low volatility stocks have higher future yields with a lower risk than relatively higher stock stocks, thus contradicting the traditional inference that attributes higher returns to higher risks. Given this, we will take a look at some of the best secure stocks to consider.
When collecting a list of the 11 best secure shares to buy according to the coverage funds, we used the Insider Monkey database of more than 1,000 coverage funds, from the fourth quarter of 2024, and we chose Mega-Cap actions with positive yields of five years and growth of revenue from next year. All these factors are considered to guarantee that stocks select low volatility and high security. In addition, we also considered actions that pay dividends to shareholders to ensure safety and reliability. Stocks are classified in ascending order of the coverage funds that are bets.
At Insider Monkey, we are obsessed with coverage funds. Why are we interested in the stocks that cover the funds? The reason is simple: our research has shown that we can overcome the market by imitating the best stock options for the best coverage funds. The strategy of our quarterly bulletin selects 14 stocks of small layers and large layers each quarter and has returned 373.4% since May 2014, surpassing its reference point at 218 percentage points (Check out more details here)).
Johnson & Johnson (JNJ) is the best safe stock to buy according to coverage funds?
A baby smiling with a wide variety of baby care products in the foreground.
Number of Holding Coverage Funds: 98
Dividend Forward: $ 5.20
Johnson & Johnson (NYSE: JNJ) is a world healthcare company focused on innovative medication and medical technologies. With headquarters in New Jersey, the company serves a large clientele, which includes retailers, wholesalers, healthcare professionals and hospitals. While pharmaceuticals cover therapy areas that include immune disorders, cancer, neurological disorders and metabolic diseases, medical devices are developed to use them in cardiovascular, orthopedic, neurovascular, general surgery and vision care fields. Incepted in 1886, the company believes that health is everything.
With changes in visionary progress, Johnson & Johnson (Nyse: Jnj) is at the helm. Management recently presented plans to invest more than $ 55 million in the United States for the next four years in the areas of manufacture, R&D and technology. This 25% increase in investment, in contrast to the last four years, shows that the company is not only an ordinary business.
Traditionally recognized as a consumer health company, Johnson & Johnson (NYSE: JNJ) has successfully gone to a health company, incorporating segments such as Pharmaceuticals and Medtech. The focus of the company on the development of medicines and devices of next generation is the one that excites us most. As part of the investment strategy, the company will build four planned manufacturing facilities.
In addition, the acquisition of intra-cellular therapies, which expands the portfolio dominated by the giant’s industry in central nervous system disorders, has the potential to contribute to more than $ 5 billion in sales of years. Johnson & Johnson (NYSE: JNJ) has also published an increase in dividends for the 63rd consecutive year in his latest results report. This commitment to the value of the returning shareholder is something that many do not realize.
In 2025, management hopes that the company will report higher levels of growth, with large contributions of hopes and other immunology assets. That said, sales growth rate is expected to be between 3.3% and 4.3%, with $ 92 million as a midpoint. The desire to change the paradigm of treatment makes Jnj a convincing case and one of the best secure stocks according to the coverage funds.
Usually jnj Rankes 11th In our list of best secure shares to buy according to the coverage funds. Although we recognize the potential of JNJ as an investment, our conviction lies in the belief that the AI actions have a greater promise to obtain higher yields and to do it in a shorter period. There is an AI stock that increased since the beginning of 2025, while the popular AI actions lost around 25%. If you are looking for a stock of IA more promising than JNJ but who sells less than five times, see our report on this Ia stock cheap.
